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Nitric oxide (NO) has been nicknamed "murderer" and "mediator" because it has toxic and
signaling properties. We review these two aspects of NO synthesis from the perspective of the
clinical infectiousdisease specialist by considering the potential of NO as an endothelium-derived
relaxing factor (EDRF) in inflammation and sepsis and its potential as an antimicrobial system.
We deviate from observations in recent authoritative reviews and point to important speciesdiffer-
ences that make it unlikely that NO servesas an EDRF mediating inflammatory vasodilatationin
humans or that NO synthesized by human phagocytes has an antimicrobial function. We propose
that in humans, NOsynthesis is moreconfined and compartmentalized than in certain other animal
species, and therefore, unwelcome toxicity, vasodilatation, or disturbance of paracrine signaling
mechanisms (i.e., modulation of phagocytic cell functions) are avoided during inflammation.
Nitric oxide (NO) has received much attention over the last
few years and was named molecule of the year in 1992 [1].
The recent scientific literature is replete with articles on the
many aspects of biological and pathological processes involv-
ing NO (reviewed in [2-4]), suggesting at times that NO might
be a jack-of-all-trades. Two aspects of the generation of NO
are of particular interest to infectious disease specialists: (I)
the potential role of NO as a cytotoxic molecule contributing
to the antimicrobial armature of phagocytes and (2) the role of
NO as a vasodilator of inflammation and mediator of septic
shock. We outline our view on the role of NO in infectious
processes in the human system. Our view deviates in some
aspects from recent authoritative analyses [2-4] and takes into
account evolutionary adaptations favorable to a utilization of
this highly reactive and toxic molecule, nicknamed "mur-
derer" [3], as a mediator.
NO is produced in human and laboratory animals by NO
synthases (NOS). NOS isoenzymes [5] have been categorized
into inducible and constitutive isoforms (table I). However,
it is apparent that activity of inducible NOS (iNOS) is also
constitutively present in many tissues, and that a constitutively
present activity of iNOS is further upregulated by enzyme-
inducing signals in these cell types [6-8]. It has also become
clear that the expression and activity of the constitutive NOS
(eNOS) are modulated as well [9].
NO as Antimicrobial Product of Mononuclear Phagocytes
NO derived in mononuclear phagocytes by a high-output
iNOS from L-arginine has been proposed to have antibacterial,
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antifungal, and antiprotozoal activity [2-4]. In animal macro-
phages, notably murine macrophages, the pathway of NO syn-
thesis and its regulation have been well characterized (reviewed
in [10]). This includes consumption of the substrates t-arginine
and O2 , production of the co-product L-citrulline, and the need
of cofactors reduced nicotinamide adenine dinucleotide phos-
phate (NADPH), flavin adenine dinucleotide (FAD), and tetra-
hydrobiopterin (B14). Most studies regarding the role of NO
formation, including its role as an antimicrobial product, de-
pend on quantitation of nitrite, an oxidation product formed
spontaneously from NO in biological systems. The main reason
for this is that nitrite can be measured by a convenient and
technically simple test that can be performed in any laboratory.
However, there are many potential pitfalls in correlating nitrite
concentrations to NO production (figure I, table 2). Artificial
accumulation of nitrite by an unknown mechanism occurs in
culture media incubated for 7 or more days without ever chang-
ing the medium. Nitrite formation is independent of the type
of medium, the presence of living cells, or the presence of
chemicals like sodium azide, and is significantly higher in the
presence ofIL-4. In media incubated at room temperature with-
out CO2 , nitrite forms even more readily (our unpublished
observation).
To demonstrate convincingly the production of NO, it is
necessary either to use cumbersome assays measuring NO by
chemoluminescence or to show that L-arginine is converted
into L-citrulline along with nitrite production [II]. To date
there is no convincing evidence that human phagocytes produce
NO in amounts that could account for antimicrobial activity.
Most, if not all, of the discrepancies in the scientific literature
in regard to NO production by human phagocytes ensue from
the confinement of these studies to the measuring of nitrite in
biological systems. In addition, as of this writing no single
laboratory has reported (based on stringent biochemical meth-
ods) that human phagocytes dispose of high-output NOS activ-
ity. Studies depending on L-arginine analogues used as "inhibi-
tors" have also not been helpful in establishing a role for NOS
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Table 1. Tissue distribution of nitric oxide synthases in animal
models.
NOTE. eNOS = constitutive nitric oxide synthase; iNOS = inducible
nitric oxide synthase; LPS = lipopolysaccharide.
* In animal and human cells.
t In animal but not in human cells.
I Not defined in human cells.
as a killing system of human phagocytes. In such experiments,
complex biological systems such as macrophages and target
cells were exposed for prolonged times to these amino acid
analogues; no appropriate control experiments were performed,
In particular, the potential effects of these antimetabolites on
protein synthesis of phagocytes or target cells and, above all,
an effect on the growth phase of microorganisms that critically
affects susceptibility to killing [12] were not addressed in such
studies.
On the basis of these reflections, it cannot be overemphasized
that, in contrast with animal studies [10] or studies on human
hepatocytes [13], scientists have failed to demonstrate, by bio-
chemical methods other than mere nitrite measurement, high-
output iNOS activity in human mononuclear phagocytes, in-
cluding tissue macrophages and microglia [11, 14, 15], as well
as in neutrophils [16]. Another basic issue related to this is the
fact that there are fundamental biochemical differences be-
tween human mononuclear phagocytes and phagocytes from
certain animal species. Human mononuclear phagocytes lack
relevant arginase or urea cycle activity, and therefore, they do
not metabolize L-arginine by this pathway [8, 11]. It has also
been shown that human mononuclear phagocytes lack the en-
zyme systems required for the synthesis ofthe BH4 , an essential
cofactor required for NO synthesis (table 3). It should be inci-
dentally noted that exogenous BH4 can not support NO synthe-
sis in human macrophages [11].
iNOS has been cloned, and the regulation of its expression
has been studied in human, murine, and rat mononuclear phago-
cytes by northern analysis, which permitted quantitative assess-
Figure 1. Spontaneous formation of nitrite in cell culture medium
(RPMI 1640) supplemented with 5% fetal bovine serum, humanre-
combinant IL-4 (200V/mL), and humanrecombinant IFN-y (500VI
mL). Cell-free medium was incubated (without changing) at 3TC,
5% CO2 for the times indicated (e). In the absence of lL-4/1FN-y,
nitriteaccumulation wasminimal (0). Thisreproducible phenomenon
wasalsoseenwithothercell culture mediasupplemented accordingly.
None of the supplements contained sodium azide. Nitrite concentra-
tion = mean ± SO from triplicate wells. Medium with and without
supplements, P < .01 for all values 2:3 daysof incubation (Student's
z-test).
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ment of specific cellular mRNA levels. While lipopolysaccha-
ride (LPS) and IFN-y were able to induce within hours long-
lasting synthesis of iNOS mRNA in phagocytes from rats and
mice, no iNOS mRNA was detectable by this method in stimu-
lated and unstimulated human phagocytes [6]. When a much
more sensitive reverse-transcriptase PCR (RT-PCR) method
was used, minute amounts of iNOS mRNA were transiently
detected upon stimulation with LPS/IFN-y in human peripheral
blood mononuclear cells that had been purified of monocytes
(but nevertheless contained 1%-2% contaminating cells of
other types). It is noteworthy that no NOS activity was detect-
able in these experiments. The minute amounts of iNOS mRNA
detected cannot be weighed against amounts found in mononu-
clear phagocytes from mice or rats [6]. In-depth studies of this
phenomenon indicate that minute amounts of iNOS message
can be detected by RT-PCR in apoptotic human mononuclear
phagocytes, but that this message is not translated into a func-
tional NOS enzyme [17, 18]. These observations confirm by
molecular methods the results of antecedent biochemical stud-
ies: human mononuclear phagocytes do not transcribe or trans-
late iNOS message at a level that could be compared with that
in phagocytes from mice or rats. Genomic analyses that so far
show similarities in the promoter regions of the rodent and
human iNOS gene, particularly in respect to IFN-y and LPS-
dependent regions, cannot explain these important species dif-
ferences [19,20]. The similarities in LPS and IFN-y-dependent
promoter regions of the NOS gene in humans and mice also
speak somewhat against the requirement for occult cytokine
IFN-'}', LPS, in combinations:
TNF-a:, IL-l, IFN-a:
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Table 2. Postulated pathways for nitric oxide production and appropriate experimental assessment.
Pathway
Nitrite formed spontaneously in
cell-free medium
Nitrite formed by ROIs
Nitrite formed by microbial terminal
oxidases or microbial nitric oxide
synthase
Nitrite formed by tumor cell target
in cytotoxicity experiments with
macrophages
Undesired antimetabolic effects of
L-arginine analogues
NOTE. ROI = reactive oxygen intermediate.
Experimental assay
Set up cell-free controls accordingly with identical supplements
to media; measure L-citrulline production.
Use phagocytes defective in ROI generation; use ROI
inhibitors; measure i-citrulline; use substrate analogues for
control.
Measure L-citrulline; control for metabolically active
microorganisms.
Use target cells without nitric oxide synthase that can be
induced during coculture by cytokines released from
macrophages.
Do not depend on analogues; use substrate antagonist only
briefly during killing; check for effects on protein synthesis
and other cell functions of phagocytes and target cells.
Table 3. Metabolic differences between murine and human macrophages concerning the L-arginine/
nitric oxide pathway.
Parameter
L-arginine consumption
Arginase activity
Ornithine production
Urea production
Nitric oxide synthase activity
Citrulline production
Cytosolic BH,
Murine macrophages
600-800 J.tmo1/106 cells
Yes
500-700 J.tmo1/106 cells
800-1,100 J.tmo1/106 cells
1.4-2.2 J.tmol/(h·106) cells
60 J.tmo1/106 cells
10-90 pmol/mg protein
Human macrophages
10-20 J.tmo11l06 cells
No
<0.1 J.tffio1/106 cells
<0.1 J.tmo1l106 cells
<0.3 J.tmoll(h·106) cells
<0.1 J.tffio1/106 cells
<0.03 pmol/mg protein
NOTE. Table was adapted from references [8, II]. BH, = tetrahydrobiopterin.
brews that would instruct viable human macrophages to express
iNOS, a concept recommended by those unwilling to accept
the undeniable species differences.
Taken together, these findings show that observations made
on the role of iNOS in the antimicrobial or antitumoral function
of phagocytes from mice, rats, or other species can not be
simply transferred to human biology. To date, there is no indi-
cation that an inducible high-output NOS is antimicrobially
operative in human phagocytes (or, incidentally, in rabbit mac-
rophages) [11].
We have previously proposed that one reason for these spe-
cies differences might be redundancy of phagocytic killing
systems that would allow for species variability [II]. Because
species differences regarding L-arginine metabolism of phago-
cytes are not restricted to iNOS but include arginase and other
enzymes of the urea cycle (table 3), these disparities must
perhaps be seen in a broader context that includes other meta-
bolic pathways. Finally, the question occurs as to whether it
was advantageous, in an evolutionary sense, to limit the synthe-
sis of NO, which might not only have antimicrobial functions
but could also become injurious to the host, mediating disas-
trous host responses such as vasodilatation during septic shock.
The Role of NO in Inflammatory Vasodilatation
In view of the major species differences in the regulation
and expression of iNOS in phagocytes, the question arises as
to whether comparable differences exist in NOSs of blood
vessels. The role of NO in the control of the vascular tone
has recently been extensively reviewed [2-4]. There is solid
evidence that NO is an endothelium-derived relaxing factor
(EDRF) mediating physiological vasodilatation in animals and
humans. In addition, vasodilatation during pathological states
such as sepsis and inflammation appears to be mediated by a
nitrovasodilator system. In several animal species, iNOS activ-
ity is induced by inflammatory mediators in endothelial cells,
an activity that is comparable to that of the high-output iNOS
in murine macrophages [2]. It is therefore conceivable that NO
also plays an important role as an inflammatory EDRF in these
species [2-4]. Comparable to observations made in macro-
phages, however, no high-output iNOS activity can be induced
in human endothelial cells by LPS, IFN-y, TNF-a, or IL-I
[21, 22], mediators that induce high-output NOS activity in
macrophages and endothelial cells from rats, mice, and cattle
or in human hepatocytes [13]. Furthermore, eNOS activity de-
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Figure 2. Evolutionary compartmentalization of vascular nitric oxide (NO) synthesis. In mice and rats, endothelial inducible nitric oxide
synthase (iNOS) present along with the constitutive enzyme (eNOS) has the potential to secreteNO in amounts comparable to toxic amounts
produced by rodent macrophages. In contrast, by compartmentalization of NO synthesis in the human vascular system into constitutive
endothelial cell (physiological, light gray arrow) and inducible smooth muscle cell (inflammatory, dark gray arrow) isoenzymes, the secretion
of large amounts of potentially toxic and randomly diffusingNO synthesized during inflammatory response can be avoided. We propose that
endothelial cells regulate NO synthesis in smooth muscle cells through tetrahydrobiopterin (BIL) to conserve inflammatory endothelium-
derived relaxing factor function through the nitrovasodilator system, Shaded areas: correspond to random NO diffusion.
creases in endothelial cells under the influence of inflammatory
stimuli, and mRNA for cNOS accordingly decreases after expo-
sure to IFN-y and/or LPS without de novo expression of iNOS
mRNA in human endothelial cells [21). Therefore, NO, in
contrast to its role in physiology, appears not to be an endothe-
lial mediator (EDRF) of inflammatory vasodilatation in the
human system. The question then arises as to where the produc-
tion of NO occurs that is responsible for the inflammatory
vasodilatation attributed to the nitrovasodilator system in hu-
mans . Because inflammatory mediators induce iNOS mRNA
synthesis in human vascular smooth muscle cells (SMCs), it
appears plausible that inflammatory vasodilatation is prompted
in humans by NO synthesized within the SMCs themselves.
NO activates soluble cytosolic guanylate cyclase in SMCs ,
resulting in an increase of the intracellular cyclic guanosine
monophosphate (cGMP) level, which in turn mediates muscle
relaxation [23, 24). Synthesis of NO at the very site of its
action within SMCs appears advantageous over a more distant
synthesis in endothelial cells. This advantage might be particu-
larly important in relation to inflammatory vasodilatation
caused by high-output iNOS, which is apt to produce large
amounts of NO. Randomly diffusing NO produced by an endo-
thelial iNOS could lead to considerable tissue damage (fig-
ure 2).
All observations made in human cell systems point out that
NO is not the inflammatory EDRF . How then is vasodilatation
controlled under inflammatory conditions? As mentioned ear-
lier, inflammatory stimuli such as LPS and IFN-y induce syn-
thesis of iNOS in vascular SMCs, but endothelial factors must
also be considered for the regulat ion of inflammatory vasodila-
tation . We have recentl y shown that BH4 , an obligatory cofac-
tor of NOS, is a highly regulated secretory product of human
endothelial cells [25). In cell culture experiments, exogenous
BH4 has been found to have regulatory effects on NO synthesis
and to augment iNOS activity as a limiting factor [8, 23). Upon
inflammatory stimuli , BH4 synthesis precedes an increase in
iNOS activity by several hours . In addition, simultaneous inhi-
bition of BH4 synthesis prevents increased iNOS activity [26].
In isolated rat aorta it has been shown that BH4 induce s a
marked and long-lasting vasodilatation [27]. These findings
made us consider the poss ibility that BH4 is an EDRF mediating
inflammatory vasodilatation in the human vascular system. BH4
secretion by human endothelial cells is markedly regulated by
a factor of 70 by activating and deactivating cytokines [25].
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Figure 3. Proposal for regulation of nitric oxide (NO) synthesis in
smooth muscle cells (SMCs) by endothelial tetrahydrobiopterin (BH4)
functioning as an endothelium-derived relaxing factor. While in-
flammatory stimuli downregulate the expression of constitutive NO
synthase (eNOS) in human vascular endothelial cells, they concomi-
tantly induce in these cells the synthesis and vectorial secretion ofBH4
in the direction of SMCs. In parallel, inflammatory stimuli upregulate
expression of inducible NO synthase (iNOS) in human vascular
SMCs. B~ is a limiting factor for NO synthesis by iNOS in inflam-
matory stimulated SMCs. Endothelium-derived BH4 acts as first mes-
senger modulating NO production in the SMCs, which as second
messenger activates soluble guanylate cyclase (sOC) to synthesize
cyclic guanosine monophosphate (cOMP), which mediates relaxation
as third messenger.
In addition, endothelial cells secrete BH4 vectorially into the
direction of vascular SMCs [23]. Furthermore, we found that
intraarterial infusion of B~ results in a local vasodilatation
that is accompanied by local consumption of L-arginine and
production of cGMP [23], strong indications that BH4 can act
as a mediator of vasodilatation through the nitrovasodilator
pathway. In this way, BH4 acts as first messenger controlling
NO production in SMCs, which as second messenger controls
the synthesis of cGMP, which regulates vasodilatation as third
messenger. Based on these observations we propose that not
NO but BH4 is an EDRF in the human vascular system inducing
inflammatory vasodilatation (figure 3).
These details are of interest because BH4 synthesis is amena-
ble to pharmacological interventions that are aimed at reducing
inflammatory vasodilatation. Accordingly, inhibition of BH4
synthesis by coumarins in murine endothelial cells results in a
reduction of NO synthesis [26]. Furthermore, there are indica-
tions that coumarins can protect animals from experimental
septic shock by decreasing NO synthesis [28]. This approach
does not necessarily affect the regulation of the vascular tone
by NO synthesized by endothelial cNOS under physiological
conditions. In septic shock, however, the selective inhibition
ofB~ synthesis might be advantageous over a global inhibi-
tion of NO synthesis by L-arginine analogues affecting both
iNOS and cNOS, which has a detrimental outcome in a canine
model of septic shock [29].
Conclusions and Possible Significance of Evolutionary
Variations in the Tissue Localization of iNOS
In conclusion, we propose that NO synthesis in humans is
more restricted than in other mammalian species such as the
rat and mouse and that not all human tissues dispose of iNOS
activity. In humans, prevention of an unhindered redundant
expression of iNOS in phagocytes circumvents undesired va-
sodilatatory signaling and toxic effects. Accordingly, compart-
mentalization of iNOS activity in human vessel walls with
restriction of NO synthesis to SMCs during inflammation could
be advantageous because it would avoid autotoxicity of NO.
Furthermore, restricted compartmentalized NO synthesis may
permit, even during inflammation, paracrine signaling that
modulates phagocyte functions [30]. Taken together, the two
observations on iNOS in human phagocytes and the vascular
system could be viewed as an evolutionary refinement in the
use of this intriguing molecule, which can be both a murderer
and an essential mediator of biological responses.
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